ClinConnect ClinConnect Logo
Search / Trial NCT06687291

Cognitive Impact Associated With Surgery For Gastric Or Esophageal Cancer

Launched by KAROLINSKA INSTITUTET · Nov 12, 2024

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

Postoperative Delirium Gastroesophageal Cancer Frailty Quality Of Life Preoperative Depression Malnutrition Sarcopenia Chemobrain Chemotherapy

ClinConnect Summary

This clinical trial is studying how common it is for patients to experience Post Operative Delirium (POD) after surgery for gastric or esophageal cancer. POD is a temporary state of confusion that can occur after surgery, and researchers want to understand how it relates to other factors like depression, frailty (being weak or fragile), quality of life, and malnutrition (not getting enough nutrients). The goal is to learn more about how these issues affect patients’ recovery and well-being after surgery.

To be eligible for this study, participants need to be at least 18 years old and diagnosed with esophageal or gastric cancer, whether or not they have received chemotherapy. They must also be able to understand the study and give their consent to participate. Those who have serious memory problems, are unable to have surgery due to cancer spread, or cannot communicate effectively will not be included. If a patient is part of the study and experiences POD, they may be asked to share their experiences in an interview during a follow-up visit after surgery. This helps researchers gather valuable information about the impact of POD on patients' lives.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients diagnosed with esophageal or gastric cancer, treated with (or without) chemotherapy and surgery.
  • Age ≥18 at the time for inclusion.
  • Participate on a voluntary basis and can (for any reason) end its participation during the study.
  • Capable of giving informed consent.
  • Exclusion Criteria:
  • Patients with preoperative cognitive dysfunction such as dementia.
  • Patients who are inoperable due to metastases.
  • Patients unable to communicate due to severely impaired hearing and/or - seeing.
  • Patients with ongoing drug and/or alcohol abuse.
  • Patients who cannot give informed consent.

About Karolinska Institutet

Karolinska Institutet is a renowned medical university located in Sweden, recognized for its commitment to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the institution focuses on translating scientific discoveries into effective treatments and therapies, emphasizing patient-centered approaches. With a strong emphasis on collaboration and interdisciplinary research, Karolinska Institutet plays a pivotal role in addressing global health challenges and improving patient outcomes, leveraging its extensive network of experts and state-of-the-art facilities to drive clinical advancements.

Locations

Huddinge, , Sweden

Huddinge, , Sweden

Patients applied

0 patients applied

Trial Officials

Maria Lampi, PhD

Principal Investigator

Karolinska Institutet

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported